Compare ADMA Biologics Inc (ADMA) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? ADMA Biologics Inc trades at $9.89 (market cap $2.22B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $244.44 (market cap $46.84B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 21.1× ADMA Biologics Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TTWO | |
|---|---|---|
Market Cap | $2.22B | $46.84B |
Sector | Health | Media |
52-Week High | $20.38 | $262.29 |
52-Week Low | $7.60 | $189.69 |
Enterprise Value | $2.29B | $47.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Take-Two Interactive (TTWO) trades at $253.57, up 2.87% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters despite a net loss, driven by NBA 2K and Grand Theft Auto (GTA) performance. Cash flow improved in 2025 due to financing activities, while debt levels remain elevated. Investor focus centers on the November 2026 GTA VI launch, with preorders termed 'unprecedented' by management (Bloomberg, August 7, 2026).
The outlook hinges on GTA VI's success, offering substantial upside to the $300.55 consensus target, but execution risks and high valuation multiples (P/S 6.94, EV/EBITDA 38.35) warrant caution. Near-term volatility may persist amid earnings uncertainty, though institutional bullishness (78.95% buy ratings) underscores long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
